(in million U.S. dollars)
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
Oncology Portfolio: #1 COMPANY IN ONCOLOGY PRODUCT SALES.
Revenue (2024):
Research and Development Update:
The Company is diversifying
its oncology portfolio and executing on its strategy which is broadly based on
three strategic pillars: immuno-oncology, precision molecular targeting and
tissue targeting.
(in million U.S. dollars)
Bristol-Myers Squibb is a specialty biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Bristol-Myers Squibb focuses on core therapeutic areas: (1) oncology with a priority in certain tumor types; (2) immunoscience with priorities in psoriasis, lupus, RA and inflammatory bowel disease; (3) cardiovascular with a priority in heart disease and (4) fibrotic disease with priorities in lung and liver.
#2 COMPANY IN ONCOLOGY PRODUCT SALES.
Oncology Portfolio: Key Marketed Products - Bristol-Myers Squibb maintains an extensive oncology portfolio for patients with solid tumors and haematological cancers.
Revenue (2024):
Bristol-Myers Squibb 2025 guidance:
(in million Swiss Franc)
Roche is one of the world’s
largest biotech companies, as well as a leading provider of in-vitro
diagnostics and a global supplier of transformative innovative solutions across
major disease areas. A global
pioneer in pharmaceuticals and diagnostics. #1 in Neurology, #3 in
Oncology & leader in Ophthalmology. Roche focuses on five
core therapeutic areas (Pharmaceuticals Division)— Oncology/Haematology,
Immunology, Neurology, Ophthalmology and Cardiovascular/Renal/Metabolism.
Oncology Portfolio (Pharmaceuticals Division): Key Marketed Products:
Revenue (2024):
2025 Guidance:
(in million U.S. dollars)
AstraZeneca is a global, science-led, patient-focused pharmaceutical company. AstraZeneca focuses on core therapeutic areas: Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I) and Vaccines & Immune Therapies (V&I)); and Rare Disease.
#4 COMPANY IN ONCOLOGY PRODUCT SALES.
Oncology Portfolio: Key Marketed Products - AstraZeneca maintains an extensive oncology portfolio for patients with solid tumors and haematological cancers. (Key disease areas: Lung cancer, Breast cancer, Ovarian cancer, Prostate cancer, Blood Cancer, Liver cancer, Pancreatic cancer)
Revenue (2024):
* Total Revenue consists of Product Sales, Alliance
Revenue and Collaboration Revenue
Long Term Outlook:
(in million U.S. dollars)
Johnson & Johnson and its subsidiaries (the Company) is engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Company is organized into two business segments: Innovative Medicine and MedTech.
Oncology Portfolio (Innovative Medicine): Johnson & Johnson maintains an extensive oncology portfolio (e.g., multiple myeloma, prostate cancer, hematologic malignancies, lung cancer and bladder cancer).
Revenue (2024):
Long-Term Guidance:
(in million U.S. dollars)
Pfizer Inc. is a research-based, global biopharmaceutical company involved in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Pfizer manages its commercial operations through a global structure consisting of three operating segments: Biopharma, PC1, and Pfizer Ignite. Among these, Biopharma is the only reportable segment. In 2024, the commercial structure within the Biopharma reportable segment included the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division.
Oncology includes:
Oncology Portfolio: Key Marketed Products:
Revenue (2024):
2025 revenue guidance: Key Product Assumptions and Considerations